Author details

Full Name

Sherri R Davies

Affiliation

ORCID

Career Start Year

1996

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37961519	Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.	bioRxiv	2023
37672882	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.	J Clin Oncol	2023
34996889	Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.	Nat Commun	2022
35393332	Early exercise in blunt chest wall trauma: protocol for a mixed-methods, multicentre, parallel randomised controlled trial (ELECT2 trial).	BMJ Open	2022
35995947	Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer.	Nat Genet	2022
36585404	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.		2022
34429404	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.	Nat Commun	2021
31542876	Research-based PAM50 signature and long-term breast cancer survival.	Breast Cancer Res Treat	2020
33371187	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.	Cancers (Basel)	2020
31196969	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability.	Mol Cell Proteomics	2019
31186261	miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study.	Cancer Epidemiol Biomarkers Prev	2019
29472518	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.	Cancer Res	2018
30429476	Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer.	Nat Commun	2018
30089255	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.	Cell Rep	2018
30181556	The prognostic effects of somatic mutations in ER-positive breast cancer.	Nat Commun	2018
29988108	Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry.	Nat Protoc	2018
27993329	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.	J Mol Diagn	2017
28348404	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.	Nat Commun	2017
28790197	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner.	Sci Signal	2017
28440318	Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.	Nat Commun	2017
29124938	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.	J Proteome Res	2017
27502118	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.	Nat Commun	2016
28691057	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).	NPJ Breast Cancer	2016
27251275	Proteogenomics connects somatic mutations to signalling in breast cancer.	Nature	2016
26867747	Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.	Methods Mol Biol	2016
26719571	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.	Clin Chem	2016
26653538	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts.	J Proteome Res	2016
26598639	QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues.	Molecular and Cellular Proteomics	2016
26503891	Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts.	Mol Cell Proteomics	2016
26631509	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer.	Mol Cell Proteomics	2016
26297356	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.	BMC Med Genomics	2015
25350482	Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes.	J Proteome Res	2015
25043054	Proteogenomic characterization of human colon and rectal cancer.	Nature	2014
25357113	Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma.	Arch Pathol Lab Med	2014
24719451	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.	Mol Cell Proteomics	2014
24055055	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell Rep	2013
22351696	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.	Clin Cancer Res	2012
19844788	Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.	Breast Cancer Res Treat	2010
20837693	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.	Clin Cancer Res	2010
20393555	Genome remodelling in a basal-like breast cancer metastasis and xenograft.	Nature	2010
19567831	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.	Proc Natl Acad Sci U S A	2009
19366795	PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.	Cancer Res	2009
19436038	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.	J Natl Cancer Inst	2009
19204204	Supervised risk predictor of breast cancer based on intrinsic subtypes.	J Clin Oncol	2009
18565769	Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta.	Osteoarthritis and Cartilage	2008
18438857	A novel tumor necrosis factor alpha-responsive CCAAT/enhancer binding protein site regulates expression of the cartilage-derived retinoic acid-sensitive protein gene in cartilage.		2008
18025304	Site-1 protease is essential for endochondral bone formation in mice.	Journal of Cell Biology	2007
17785538	Computational identification and functional validation of regulatory motifs in cartilage-expressed genes.	Genome Res	2007
16250001	A promoter element of the CD-RAP gene is required for repression of gene expression in non-cartilage tissues in vitro and in vivo.	Journal of Cellular Biochemistry	2006
16214313	In vivo human Cartilage oligomeric matrix protein (COMP) promoter activity.	Matrix Biology	2005